Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,960 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, Brown AS, Marcozzi-Pierce K, Shah D, Slager AM, Sylvester AJ, Khan A, Broderick KE, Juba RJ, Herring TA, Boyer J, Lee J, Sardesai NY, Weiner DB, Bagarazzi ML. Trimble CL, et al. Among authors: boyer j. Lancet. 2015 Nov 21;386(10008):2078-2088. doi: 10.1016/S0140-6736(15)00239-1. Epub 2015 Sep 17. Lancet. 2015. PMID: 26386540 Free PMC article. Clinical Trial.
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100.
Morrow MP, Kraynyak KA, Sylvester AJ, Shen X, Amante D, Sakata L, Parker L, Yan J, Boyer J, Roh C, Humeau L, Khan AS, Broderick K, Marcozzi-Pierce K, Giffear M, Lee J, Trimble CL, Kim JJ, Sardesai NY, Weiner DB, Bagarazzi ML. Morrow MP, et al. Among authors: boyer j. Mol Ther Oncolytics. 2016 Nov 30;3:16025. doi: 10.1038/mto.2016.25. eCollection 2016. Mol Ther Oncolytics. 2016. PMID: 28054033 Free PMC article.
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Knoblock DM, Bauml JM, Weinstein GS, Lin A, Boyer J, Sakata L, Tan S, Anton A, Dickerson K, Mangrolia D, Vang R, Dallas M, Oyola S, Duff S, Esser M, Kumar R, Weiner D, Csiki I, Bagarazzi ML. Aggarwal C, et al. Among authors: boyer j. Clin Cancer Res. 2019 Jan 1;25(1):110-124. doi: 10.1158/1078-0432.CCR-18-1763. Epub 2018 Sep 21. Clin Cancer Res. 2019. PMID: 30242022 Free PMC article. Clinical Trial.
Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population.
Hollenberg RK, Krieger DR, Samuels R, Kraynyak K, Sylvester A, Morrow M, Boyer J, Dallas M, Bhuyan PK. Hollenberg RK, et al. Among authors: boyer j. Hum Vaccin Immunother. 2020 Jun 2;16(6):1404-1412. doi: 10.1080/21645515.2019.1695459. Epub 2019 Dec 20. Hum Vaccin Immunother. 2020. PMID: 31860383 Free PMC article. Clinical Trial.
A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.
Hasan Y, Furtado L, Tergas A, Lee N, Brooks R, McCall A, Golden D, Jolly S, Fleming G, Morrow M, Kraynyak K, Sylvester A, Arif F, Levin M, Schwartz D, Boyer J, Skolnik J, Esser M, Kumar R, Bagarazzi M, Weichselbaum R, Spiotto M. Hasan Y, et al. Among authors: boyer j. Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):487-498. doi: 10.1016/j.ijrobp.2020.02.031. Epub 2020 Mar 7. Int J Radiat Oncol Biol Phys. 2020. PMID: 32151670 Free PMC article. Clinical Trial.
Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL.
Bhuyan PK, Dallas M, Kraynyak K, Herring T, Morrow M, Boyer J, Duff S, Kim J, Weiner DB. Bhuyan PK, et al. Among authors: boyer j. Hum Vaccin Immunother. 2021 May 4;17(5):1288-1293. doi: 10.1080/21645515.2020.1823778. Epub 2020 Nov 11. Hum Vaccin Immunother. 2021. PMID: 33175656 Free PMC article. Clinical Trial.
Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.
Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, Knott C, Lin F, Boyer JD, Draghia-Akli R, White CJ, Kim JJ, Weiner DB, Sardesai NY. Bagarazzi ML, et al. Among authors: boyer jd. Sci Transl Med. 2012 Oct 10;4(155):155ra138. doi: 10.1126/scitranslmed.3004414. Sci Transl Med. 2012. PMID: 23052295 Free PMC article. Clinical Trial.
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy.
Morrow MP, Kraynyak KA, Sylvester AJ, Dallas M, Knoblock D, Boyer JD, Yan J, Vang R, Khan AS, Humeau L, Sardesai NY, Kim JJ, Plotkin S, Weiner DB, Trimble CL, Bagarazzi ML. Morrow MP, et al. Among authors: boyer jd. Clin Cancer Res. 2018 Jan 15;24(2):276-294. doi: 10.1158/1078-0432.CCR-17-2335. Epub 2017 Oct 30. Clin Cancer Res. 2018. PMID: 29084917 Free PMC article.
A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).
Alvarez RD, Huh WK, Bae S, Lamb LS Jr, Conner MG, Boyer J, Wang C, Hung CF, Sauter E, Paradis M, Adams EA, Hester S, Jackson BE, Wu TC, Trimble CL. Alvarez RD, et al. Among authors: boyer j. Gynecol Oncol. 2016 Feb;140(2):245-52. doi: 10.1016/j.ygyno.2015.11.026. Epub 2015 Nov 23. Gynecol Oncol. 2016. PMID: 26616223 Free PMC article. Clinical Trial.
1,960 results